Cannara Biotech Valuation
| LOVFF Stock | USD 0.59 0.08 15.69% |
Cannara Biotech is overvalued. Cannara Biotech shows a prevailing Real Value of $0.42 per share. The current price of the firm is $0.59. Our model approximates the value of Cannara Biotech from analyzing the firm fundamentals such as Return On Equity of 0.0434, current valuation of 94.03 M, and Profit Margin of 0.07 % as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Cannara Biotech's price fluctuation is out of control at this time. Calculation of the real value of Cannara Biotech is based on 3 months time horizon. Increasing Cannara Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cannara otc stock is determined by what a typical buyer is willing to pay for full or partial control of Cannara Biotech. Since Cannara Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cannara OTC Stock. However, Cannara Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.59 | Real 0.42 | Hype 0.51 | Naive 0.59 |
The real value of Cannara OTC Stock, also known as its intrinsic value, is the underlying worth of Cannara Biotech OTC Stock, which is reflected in its stock price. It is based on Cannara Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cannara Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cannara Biotech helps investors to forecast how Cannara otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cannara Biotech more accurately as focusing exclusively on Cannara Biotech's fundamentals will not take into account other important factors: Cannara Biotech Total Value Analysis
Cannara Biotech is now forecasted to have takeover price of 94.03 M with market capitalization of 63.27 M, debt of 46.19 M, and cash on hands of 3.88 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cannara Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
94.03 M | 63.27 M | 46.19 M | 3.88 M |
Cannara Biotech Investor Information
About 48.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Cannara Biotech had not issued any dividends in recent years. The entity had 1:10 split on the 13th of February 2023. Cannara Biotech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Cannara Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cannara Biotech has an asset utilization ratio of 28.53 percent. This implies that the OTC Stock is making $0.29 for each dollar of assets. An increasing asset utilization means that Cannara Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Cannara Biotech Ownership Allocation
Cannara Biotech holds a total of 877.48 Million outstanding shares. Cannara Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cannara Biotech Profitability Analysis
The company reported the revenue of 35.84 M. Net Income was 2.31 M with profit before overhead, payroll, taxes, and interest of 17.33 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cannara Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cannara Biotech and how it compares across the competition.
About Cannara Biotech Valuation
The otc valuation mechanism determines Cannara Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Cannara Biotech. We calculate exposure to Cannara Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cannara Biotech's related companies.Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. Cannara Biotech is traded on OTC Exchange in the United States.
8 Steps to conduct Cannara Biotech's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Cannara Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cannara Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cannara Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cannara Biotech's revenue streams: Identify Cannara Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cannara Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cannara Biotech's growth potential: Evaluate Cannara Biotech's management, business model, and growth potential.
- Determine Cannara Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cannara Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Cannara Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cannara Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 877 M | |
| Quarterly Earnings Growth Y O Y | -0.292 | |
| Retained Earnings | -26.3 M |
Complementary Tools for Cannara OTC Stock analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |